What Is Angiopoietin? Definition and What Research Reports
Angiopoietin refers to a small family of secreted glycoproteins — chiefly angiopoietin-1 and angiopoietin-2 — that bind the Tie2 receptor on endothelial cells and help regulate blood-vessel stability and permeability. A structurally related but functionally separate family, the angiopoietin-like proteins (ANGPTLs), acts mainly on lipid metabolism. Published work has examined the angiopoietin–Tie2 axis in critical illness, sepsis, vascular anomalies, kidney disease, metabolic disease, the nervous system and cancer biology. Most literature is descriptive or mechanistic rather than interventional.
Definition
Angiopoietin is the name given to a family of secreted glycoproteins that act as ligands for Tie2 (TEK), a receptor tyrosine kinase expressed largely on vascular endothelial cells. The best-characterised members are angiopoietin-1 (ANGPT1) and angiopoietin-2 (ANGPT2), with angiopoietin-4 also described in humans. A 2017 Cell SnapShot review summarised the angiopoietins and their functions as regulators of vascular quiescence, remodelling and endothelial barrier behaviour through Tie2 signalling (PMID 29053972). In short, the term describes endogenous signalling proteins of the blood-vessel wall rather than a single defined drug or research compound.
This page is for educational purposes only and is not medical advice; consult a licensed physician for any health question. Nothing here describes how any substance should be used.
What Class of Molecule Is It, and Where Does It Come From?
Angiopoietins are full-length proteins, not short synthetic peptides. They are produced endogenously: angiopoietin-1 is largely derived from perivascular cells such as pericytes and smooth muscle cells, while angiopoietin-2 is stored in and released from endothelial cells themselves, where it can behave as a context-dependent partial agonist or antagonist at Tie2, as outlined in the 2017 SnapShot overview (PMID 29053972). Because they are glycosylated, multimeric proteins, they sit at the large end of the "peptide" spectrum and are typically studied as recombinant proteins, genetic models, or circulating biomarkers rather than as compact peptide analogues.
| Term | What it refers to | Primary receptor | Source cited |
|---|---|---|---|
| Angiopoietin-1 (ANGPT1) | Tie2 ligand associated with vessel stabilisation in reviews of the family | Tie2 / TEK | PMID 29053972 |
| Angiopoietin-2 (ANGPT2) | Endothelium-derived Tie2 ligand described as context-dependent | Tie2 / TEK | PMID 29053972 |
| Angiopoietin-like proteins (ANGPTL1–8) | Structurally related family reviewed separately in atherosclerosis literature | Do not signal through Tie2 in the same manner | PMID 34153276 |
How the Term Is Used in Peptide and Protein Research
In the research literature, "angiopoietin" is used in three broad ways. First, as a biomarker: circulating angiopoietin-2 concentrations are measured in blood and correlated with clinical outcomes. Second, as a pathway: authors refer to the "angiopoietin–Tie2 axis" when describing endothelial barrier regulation. Third, as a target: preclinical and translational work asks whether modulating the axis changes vascular permeability or tumour vasculature. A 2020 review in Critical Care Clinics examined the angiopoietin–Tie2 pathway specifically in the setting of critical illness and described it as a regulator of endothelial barrier integrity in that context (PMID 32172809).
Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.
Try it freeWhat the Published Literature Reports
Critical illness, sepsis and capillary leak
A large share of the angiopoietin literature concerns acute vascular dysfunction. In a 2023 study published in Annals of Intensive Care, researchers reported that angiopoietin-2 was associated with capillary leak and predicted complications after cardiac surgery (PMID 37552379). Mechanistic work has also examined how angiopoietin-2 is processed: a 2025 Journal of Clinical Investigation paper reported that cathepsin K cleavage of angiopoietin-2 generated Tie2 antagonist fragments described as detrimental in sepsis (PMID 40029709). Separately, a 2024 Nature Microbiology study reported that angiopoietin-like 4 protected against endothelial dysfunction during bacterial sepsis (PMID 39103571). Taken together, the study literature in this area treats the pathway as a candidate mediator of vascular leak rather than an established therapeutic target.
Vascular anomalies
Angiopoietin-2 also appears in clinical practice literature as a measured analyte. A 2024 article in Pediatric Blood & Cancer described how angiopoietin-2 was used in the diagnosis and management of vascular anomalies (PMID 38439088). That paper is a practice-pattern description rather than a controlled trial.
Kidney and metabolic biology
Genetic and cell-specific models have been used to dissect where angiopoietin-2 acts. A 2026 paper in the Journal of the American Society of Nephrology examined cell-specific roles of angiopoietin-2 in chronic kidney disease (PMID 41979897). In metabolic research, a 2022 Molecular Metabolism study reported that selective adipocyte loss of angiopoietin-2 prompted female-specific obesity and metabolic syndrome in its model (PMID 36055577). These findings are model-specific and were not reported as human outcomes.
Nervous system
Beyond the vasculature, a 2019 review in Neuroscience discussed angiopoietin as a novel neuroprotective and neurotrophic agent, extending the discussion past purely angiogenic roles (PMID 31152935). A 2019 Journal of Neuroimmunology paper examined angiopoietin-like proteins in multiple sclerosis (PMID 30784773).
Cancer biology
Because tumours depend on vascular supply, angiopoietins have been reviewed in oncology. A 2007 review in the European Journal of Surgical Oncology surveyed angiopoietins in malignancy (PMID 16962282). As with the other sections above, the review format means it summarised prior work rather than generating new outcome data.
Angiopoietin-Like Proteins (ANGPTLs): A Related but Separate Family
Readers encountering the term frequently run into angiopoietin-like proteins, abbreviated ANGPTL1 through ANGPTL8. They share a structural resemblance to the angiopoietins but are generally discussed in a different physiological context, particularly lipid handling and inflammation. A 2021 review in Clinica Chimica Acta examined angiopoietin-like proteins in atherosclerosis (PMID 34153276), and the 2019 neuroimmunology paper noted above addressed the same family in multiple sclerosis (PMID 30784773). Conflating the two families is a common source of confusion when reading abstracts, because "ANGPT2" and "ANGPTL2" are different molecules.
Tracking research? Log entries with dates, lots and notes — records, never plans.
Get the appAngiopoietin Research and Adverse Events: What Studies Report
The verified literature summarised on this page is largely observational, mechanistic or review-based, and it does not describe administration of angiopoietin products to healthy people. Where harm-adjacent findings appear, they concern endogenous biology rather than a dosed compound: researchers reported that angiopoietin-2 was associated with capillary leak and predicted complications after cardiac surgery (PMID 37552379), and a separate study reported that proteolytic fragments of angiopoietin-2 generated by cathepsin K acted as Tie2 antagonists described as detrimental in sepsis (PMID 40029709). A model study reported that selective adipocyte loss of angiopoietin-2 prompted female-specific obesity and metabolic syndrome (PMID 36055577). No human dosing, tolerability or safety schedule is described in the sources cited here, and none should be inferred.
Limitations of the Evidence
- Different families, different meanings. Findings about ANGPTL proteins do not transfer to ANGPT1/ANGPT2, as the separate reviews make clear (PMID 34153276).
- Biomarker association is not causation. Studies reporting that angiopoietin-2 predicted post-surgical complications measured correlation with outcomes (PMID 37552379).
- Animal and cell models dominate. Several key mechanistic findings were reported in experimental sepsis and genetic knockout systems (PMID 39103571).
- Context dependence. The same ligand has been described as acting differently depending on tissue and disease state (PMID 29053972).
Want the full course? Every compound, evidence-graded and cited, inside PeptideU.
Start learning freeReferences
- SnapShot: Angiopoietins and Their Functions (Cell, 2017)
- The Angiopoietin-Tie2 Pathway in Critical Illness (Critical Care Clinics, 2020)
- Angiopoietin-2 is associated with capillary leak and predicts complications after cardiac surgery (Annals of Intensive Care, 2023)
- Cathepsin K cleavage of angiopoietin-2 creates detrimental Tie2 antagonist fragments in sepsis (The Journal of Clinical Investigation, 2025)
- Angiopoietin-like 4 protects against endothelial dysfunction during bacterial sepsis (Nature Microbiology, 2024)
- How we use angiopoietin-2 in the diagnosis and management of vascular anomalies (Pediatric Blood & Cancer, 2024)
- Cell-Specific Roles of Angiopoietin-2 in CKD (Journal of the American Society of Nephrology, 2026)
- Selective adipocyte loss of Angiopoietin-2 prompts female-specific obesity and metabolic syndrome (Molecular Metabolism, 2022)
- Angiopoietin: A Novel Neuroprotective/Neurotrophic Agent (Neuroscience, 2019)
- Angiopoietin-like proteins in multiple sclerosis (Journal of Neuroimmunology, 2019)
- Angiopoietin-like proteins in atherosclerosis (Clinica Chimica Acta, 2021)
- Angiopoietins in malignancy (European Journal of Surgical Oncology, 2007)
Frequently asked questions
What does "angiopoietin" actually mean?▾
It is the collective name for a family of secreted glycoproteins that bind the Tie2 receptor tyrosine kinase on endothelial cells. A 2017 Cell SnapShot summarised the angiopoietins and their functions in vascular quiescence and remodelling (PMID 29053972). The term describes endogenous signalling proteins of the blood-vessel wall, not a single named drug product.
Is angiopoietin the same as an angiopoietin-like protein?▾
No. Angiopoietin-like proteins (ANGPTL1–8) are structurally related but discussed in different physiological contexts. A 2021 review examined angiopoietin-like proteins in atherosclerosis (PMID 34153276), and a 2019 paper examined them in multiple sclerosis (PMID 30784773). Abbreviations such as ANGPT2 and ANGPTL2 refer to distinct molecules and should not be treated interchangeably when reading abstracts.
Why is angiopoietin-2 measured in hospital settings?▾
It has been studied as a circulating marker of endothelial barrier disturbance. Researchers reported that angiopoietin-2 was associated with capillary leak and predicted complications after cardiac surgery (PMID 37552379). A 2024 article also described how angiopoietin-2 was used in the diagnosis and management of vascular anomalies (PMID 38439088). These are measurement and practice descriptions, not treatment recommendations.
What has research reported about angiopoietin in sepsis?▾
A 2025 study reported that cathepsin K cleavage of angiopoietin-2 created Tie2 antagonist fragments described as detrimental in sepsis (PMID 40029709). Separately, a 2024 study reported that angiopoietin-like 4 protected against endothelial dysfunction during bacterial sepsis (PMID 39103571). A 2020 review framed the angiopoietin–Tie2 pathway as relevant to critical illness generally (PMID 32172809).
Does angiopoietin have roles outside blood vessels?▾
The literature extends beyond angiogenesis. A 2019 review discussed angiopoietin as a novel neuroprotective and neurotrophic agent (PMID 31152935). In metabolic research, a 2022 study reported that selective adipocyte loss of angiopoietin-2 prompted female-specific obesity and metabolic syndrome in its model (PMID 36055577). Both remain areas of active investigation rather than settled physiology.
Is angiopoietin studied in cancer research?▾
Yes, chiefly because tumours depend on vascular supply. A 2007 review in the European Journal of Surgical Oncology surveyed angiopoietins in malignancy (PMID 16962282). That paper summarised prior literature rather than reporting new outcome data, and the broader family review from 2017 described angiopoietin signalling as context-dependent across tissues (PMID 29053972).
Are there human dosing studies of angiopoietin?▾
The sources summarised on this page do not describe administration of angiopoietin to healthy people or dosing schedules. They are mechanistic studies, animal and cell models, biomarker analyses and narrative reviews, including work on cell-specific roles of angiopoietin-2 in chronic kidney disease (PMID 41979897). This page is educational only and is not medical advice.
Track it. Calculate it. Actually understand it.
References
This page summarises published research for education — it is not medical advice, and nothing here is a recommendation to use, purchase, or dose any substance. Study parameters described are what researchers reported, not instructions. Consult a qualified clinician before any health decision.